- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc stock price live, this page displays NASDAQ CLRB stock exchange data. View the CLRB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectar Biosciences Inc real time stock price chart below.
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 5.1100.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is ""CLRB.""
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 5.1100.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is ""CLRB.""
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
NASDAQ
Currency in USD
5.1100
+0.3500(+7.35%)
Real-time Data·
Fair Value
An estimate of a Cellectar Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.7201
5.1300
52 wk Range
4.1100
68.7000
CLRB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CLRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Cellectar Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.72015.1300
52 wk Range
4.110068.7000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLRB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cellectar Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
47.0000
Upside
+819.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Cellectar Biosciences Inc Company Profile
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences Inc Earnings Call Summary for Q2/2025
- SelectR Biosciences reported Q2 2025 net loss of $5.4M ($3.39/share), missing EPS forecast of -$0.13; stock rose 7.24% premarket
- R&D expenses reduced to $2.4M from $7.3M YoY; G&A expenses down to $3.6M from $6.4M; cash position at $11M as of June 30, 2025
- Company plans NDA submission for Iapofacine I-131 in late 2025/early 2026; confirmatory study estimated at $40-45M
- Phase I trials for CLR125 and CLR225 planned for late 2025/early 2026; secured long-term isotope supply agreement
- CEO emphasized focus on radiopharmaceutical therapies; COO highlighted promising CLR125 biodistribution with 25-30% tumor uptake
Last Updated: 14/08/2025, 14:34
Read Full TranscriptCompare CLRB to Peers and Sector
Metrics to compare | CLRB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLRBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −3.0x | −0.5x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price/Book | 2.8x | 1.5x | 2.6x | |
Price / LTM Sales | - | 139.2x | 3.3x | |
Upside (Analyst Target) | - | 171.4% | 38.7% | |
Fair Value Upside | Unlock | 6.0% | 5.0% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 47.0000
(+819.77% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-3.39 / -0.13
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Cellectar Biosciences Trade On?
Cellectar Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cellectar Biosciences?
The stock symbol for Cellectar Biosciences is "CLRB."
What Is the Cellectar Biosciences Market Cap?
As of today, Cellectar Biosciences market cap is 15.64M.
What Is Cellectar Biosciences's Earnings Per Share (TTM)?
The Cellectar Biosciences EPS (TTM) is -19.86.
From a Technical Analysis Perspective, Is CLRB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Cellectar Biosciences Stock Split?
Cellectar Biosciences has split 6 times.
How Many Employees Does Cellectar Biosciences Have?
Cellectar Biosciences has 11 employees.
What is the current trading status of Cellectar Biosciences (CLRB)?
As of 27 Aug 2025, Cellectar Biosciences (CLRB) is trading at a price of 5.11, with a previous close of 4.76. The stock has fluctuated within a day range of 4.72 to 5.13, while its 52-week range spans from 4.11 to 68.70.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.